Notice: unserialize(): Error at offset 2 of 31 bytes in /data/html/www_bioworld_com/includes/bootstrap.inc on line 559 Notice: unserialize(): Error at offset 2753 of 5598 bytes in /data/html/www_bioworld_com/includes/bootstrap.inc on line 559 Mologen Shares Rise on Cancer Immunotherapy Phase II Data | BioWorld

Login to Your Account



Mologen Shares Rise on Cancer Immunotherapy Phase II Data

By Cormac Sheridan
Staff Writer

Wednesday, May 16, 2012
Shares in Mologen AG jumped 17 percent to a 52-week high Monday on news that the company's DNA-based cancer immunotherapy, MGN1703, hit the primary endpoint, a prolongation of progression-free survival (PFS), in a Phase II trial in patients with metastatic colorectal cancer (CRC).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription